Track Eris Lifesciences Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Eris Lifesciences Limited ERIS.NS · Stock Open Eris Lifesciences Limited in new tab

1431.10 INR
P/E
31.66
EPS
45.20
Yield
0.50%
Safety Score
21
P/B
5.01
ROE
18.07
Beta
-0.11
Target Price
1696.60 INR
Loading chart...
Key Metrics
Earnings dateAug. 11, 2026
P/E31.66
EPS45.20
Book Value285.48
Price to Book5.01
Debt/Equity60.55
% Insiders69.693%
Growth
Revenue Growth0.07%
Earnings Growth2.00%
Estimates
Forward P/E23.41
Forward EPS61.14
Target Mean Price1696.60
Dividend
Dividend Yield0.50%
Annual dividends7.21 INR
Ex-Div. DateMay 29, 2026

DCF Valuation

Tweak assumptions to recompute fair value for Eris Lifesciences Limited (ERIS.NS)
Currency: INR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Eris Lifesciences Limited Logo Eris Lifesciences Limited Analysis (ERIS.NS)

India Health Care Official Website Stock

Is Eris Lifesciences Limited a good investment? Eris Lifesciences Limited (ERIS.NS) is currently trading at 1431.10 INR. Market analysts have a consensus price target of 1696.60 INR. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 31.66. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Eris Lifesciences Limited is expected to release its next earnings report on Aug. 11, 2026. The market consensus estimate for Forward EPS is 61.14.

For income investors, Eris Lifesciences Limited pays a dividend yield of 0.50%.

Investor FAQ

Does Eris Lifesciences Limited pay a dividend?

Yes, it pays an annual dividend of 7.21 INR (0.50% yield).

What asset class is Eris Lifesciences Limited?

Eris Lifesciences Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 11, 2026. The company currently has a trailing EPS of 45.20.

Company Profile

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Exchange Ticker
NSI (India) ERIS.NS
Trades
Dividend Yield
0.50%
Annual Dividends
7.21INR
Next Ex. Div Date
May 29, 2026
Dividend History paid per year (INR)
Historical Dividends
Year Total Dividends
2027
7.21 INR
June 21, 2027 (estimated) 7.2100
2026
7.21 INR
June 19, 2026 7.2100
2025
7.35 INR
Feb. 28, 2025 7.3500
2022
7.35 INR
Sept. 4, 2022 7.3500
2021
6.01 INR
Aug. 28, 2021 6.0100
2020
8.37 INR
Sept. 3, 2020 5.5000
April 10, 2020 2.8700
Upcoming Dividends
Name Payment Date Status Amount
Eris Lifesciences Limited Jun 19, 2026 7.21 INR
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion